{
  "success": true,
  "pagesUsed": [
    7,
    8,
    9,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-2.5-pro",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participant...",
        "text": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accu...",
        "text": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accumulation and at steady state periods versus the pretreatment baseline in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in partici...",
        "text": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and...",
        "text": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in par...",
        "text": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants...",
        "text": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate ...",
        "text": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate (PUF) molybdenum (as surrogate measures of ALXN1840, 15 mg and 30 mg) in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg...",
        "text": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8",
          "ep_9",
          "ep_10",
          "ep_11",
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with ...",
        "text": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with WD",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Determine the effect of treatment duration on copper balance in participants with WD",
        "text": "Determine the effect of treatment duration on copper balance in participants with WD",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma i...",
        "text": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma in participants with WD",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "",
        "text": "Mean daily copper balance where copper balance is measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) during ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "",
        "text": "Change in mean daily copper balance as measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) from pretreatment baseline (Days -4 through -1) and ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "",
        "text": "Copper quantified in food, drink, feces, and urine, including plasma total and labile bound copper (LBC) during ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "",
        "text": "Molybdenum quantified in food, drink, feces, and urine, plasma total molybdenum at ALXN1840 steady state",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_5",
        "name": "",
        "text": "Mean daily molybdenum balance as demonstrated through measurement of molybdenum intake (in food, drink and ALXN1840), and molybdenum output (feces and urine) representing ALXN1840 steady state",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_6",
        "name": "",
        "text": "Accumulation of molybdenum as determined by molybdenum balance",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_7",
        "name": "",
        "text": "PK parameters for plasma total and PUF-molybdenum",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_8",
        "name": "",
        "text": "Treatment emergent adverse events (TEAEs)/serious adverse events (SAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "",
        "text": "Clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "",
        "text": "Physical examinations",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "",
        "text": "Heart rate, intervals (PR, QRS, QT and QTc), and clinically significant electrocardiogram (ECG) findings as determined by triplicate 12-lead ECG",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "",
        "text": "Vital sign assessments (blood pressure and heart rate)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "",
        "text": "Assess dose response of ALXN1840 on copper balance focusing on copper balance",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "",
        "text": "Determine the effect of time following initiation of ALXN1840 treatment on copper balance",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_15",
        "name": "",
        "text": "Ceruloplasmin, ceruloplasmin-bound copper, and LBC: Change in ceruloplasmin at Days 1, 8, 25, 29, 36, and Day 39 compared with predose",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 7,
      "exploratoryObjectives": 3,
      "totalEndpoints": 15,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "text": "Assess net copper balance with daily repeat-dose ALXN1840 treatment (15 mg and 30 mg) in participants with Wilson disease (WD)",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "text": "Assess change in copper balance in response to ALXN1840 15 mg/day and 30 mg/day during ALXN1840 accumulation and at steady state periods versus the pretreatment baseline in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "text": "Investigate the effect of ALXN1840 (15 mg/day and 30 mg/day) on the disposition of copper in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "text": "Investigate the effect of ALXN1840 on the disposition of molybdenum at steady state at 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "text": "Assess steady-state total molybdenum balance as a measure of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "text": "Assess accumulation of molybdenum with ALXN1840 treatment at 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "text": "Determine the steady-state plasma pharmacokinetic (PK) of total molybdenum and plasma ultrafiltrate (PUF) molybdenum (as surrogate measures of ALXN1840, 15 mg and 30 mg) in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "text": "Evaluate the safety and tolerability of repeated-dose administration of ALXN1840 15 mg/day and 30 mg/day in participants with WD",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_8",
          "ep_9",
          "ep_10",
          "ep_11",
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "text": "Determine dose response of ALXN1840 15 mg/day and 30 mg/day for copper balance in participants with WD",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Exploratory Objective"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "text": "Determine the effect of treatment duration on copper balance in participants with WD",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Exploratory Objective"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "text": "Assess the effects of ALXN1840 on ceruloplasmin, ceruloplasmin-bound copper LBC profiles in plasma in participants with WD",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Exploratory Objective"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "text": "Mean daily copper balance where copper balance is measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) during ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "text": "Change in mean daily copper balance as measured by the calculated difference between copper intake (in food and drink) and copper output (in feces and urine) from pretreatment baseline (Days -4 through -1) and ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "text": "Copper quantified in food, drink, feces, and urine, including plasma total and labile bound copper (LBC) during ALXN1840 accumulation and steady-state periods for each dose",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "text": "Molybdenum quantified in food, drink, feces, and urine, plasma total molybdenum at ALXN1840 steady state",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "text": "Mean daily molybdenum balance as demonstrated through measurement of molybdenum intake (in food, drink and ALXN1840), and molybdenum output (feces and urine) representing ALXN1840 steady state",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "text": "Accumulation of molybdenum as determined by molybdenum balance",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "text": "PK parameters for plasma total and PUF-molybdenum",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "text": "Treatment emergent adverse events (TEAEs)/serious adverse events (SAEs)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_9",
        "text": "Clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_10",
        "text": "Physical examinations",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_11",
        "text": "Heart rate, intervals (PR, QRS, QT and QTc), and clinically significant electrocardiogram (ECG) findings as determined by triplicate 12-lead ECG",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_12",
        "text": "Vital sign assessments (blood pressure and heart rate)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_13",
        "text": "Assess dose response of ALXN1840 on copper balance focusing on copper balance",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Exploratory Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_14",
        "text": "Determine the effect of time following initiation of ALXN1840 treatment on copper balance",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Exploratory Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_15",
        "text": "Ceruloplasmin, ceruloplasmin-bound copper, and LBC: Change in ceruloplasmin at Days 1, 8, 25, 29, 36, and Day 39 compared with predose",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Exploratory Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}